November 2019 in “Harper's Textbook of Pediatric Dermatology” The document is a detailed medical reference on skin and genetic disorders.
Changes in skin bacteria can affect hair loss and new treatments targeting these bacteria may prevent balding without sexual side effects.
July 2018 in “Elsevier eBooks” The most common cause of hair loss in children is tinea capitis, followed by alopecia areata and telogen effluvium.
January 2024 in “Journal of applied biological chemistry” Glehnia littoralis and Andrographis paniculata extracts can significantly boost hair growth.
January 2022 in “Medical research archives” Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.
December 2022 in “Scholars journal of applied medical sciences” Dutasteride 0.5mg improves hair growth in 78% of people with hair loss, but may cause sexual problems in some.
November 2020 in “Postepy Dermatologii I Alergologii” Sulfotransferase SULT1A1 activity may predict minoxidil treatment success for hair loss.
102 citations,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Restoring hair bulb immune privilege is crucial for managing alopecia areata.
16 citations,
May 2019 in “International Journal of Women's Dermatology” The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.
10 citations,
October 2015 in “Medicina Clínica (english Edition)” Recombinant human epidermal growth factor is versatile, effective, and safe for long-term skin and mucosal treatments.
1 citations,
September 2023 in “Clinical, cosmetic and investigational dermatology” Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
December 2023 in “Dermatology and therapy” Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
May 2023 in “Dermatology and therapy” The document concludes that identifying the cause of eyebrow and eyelash loss is key to treating it and improving quality of life.
January 2015 in “Journal of clinical & experimental dermatology research” A protein combining parathyroid hormone and collagen helped hair regrow in mice with a hair loss condition.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
1 citations,
August 2022 in “JAAD Case Reports” A woman's complete hair loss condition improved after recovering from COVID-19.
2 citations,
August 2022 in “JAAD case reports” COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
December 2023 in “Journal of dermatology” Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
20 citations,
March 2021 in “Drug design, development and therapy” Topical immunotherapy can treat alopecia areata, but its effectiveness varies and the exact mechanism is unclear.
2 citations,
July 2023 in “Journal of dermatology” Alopecia areata causes a significant economic burden in Japan, mainly due to productivity loss.
1 citations,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
1 citations,
June 2023 in “Dermatology and therapy” People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
May 2023 in “Advances in medicine” Alopecia areata significantly impacts patients' mental health and quality of life.
20 citations,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
January 2024 in “JEADV clinical practice” The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.
December 2024 in “Journal of Clinical Medicine” Minoxidil shows promise for alopecia areata, but more research is needed before it can be recommended as a primary treatment.
31 citations,
July 2021 in “ImmunoTargets and therapy” Alopecia areata is an incurable autoimmune condition causing hair loss, with research aiming for better treatments.